What Procos does

Procos S.P.A. is an Italian Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs), advanced intermediates, and Highly Potent APIs (HPAPIs), headquartered at a 155,000 sq. meter cGMP facility in Cameri (Novara), Italy. Founded in 1945 and operating under the direction and coordination of Japanese conglomerate CBC Co. Ltd. since 2006, the company serves two complementary customer segments: innovator pharmaceutical companies requiring custom synthesis, process development, and scale-up from preclinical through commercial supply, and generic pharmaceutical companies sourcing from a commercial portfolio of 30–40+ APIs spanning antispasmodic, antihypertensive, antipsychotic, antiemetic, antiarrythmic, antiviral, and oncology therapeutic classes.

The technical platform comprises six independent production departments with more than 50 production lines, 630 m3 of reactor capacity plus 200 m3 of auxiliary equipment, and an annual output capacity above 2,500 tonnes. Differentiated capabilities include HPAPI units with Occupational Exposure Limits as low as 1 ng/m³ (covering Kilolab GMP, Small GMP, R&D lab, and QC units), industrial-scale Flow Chemistry, high-pressure hydrogenators up to 60 bar, Chemspeed robotic laboratory automation, and calorimetric process safety testing. Manufacturing is audited and approved by AIFA, US FDA, and Japan PMDA, with regulatory filings active across Europe, the United States, Japan, Korea, Canada, Brazil, Australia, Taiwan, and China. An €80 million R11 multipurpose unit is in construction as of 2025, lifting total capacity to 700 m3.

Procos monetizes through two revenue streams: project-based custom synthesis / CDMO services (preclinical through commercial supply, pricing quote-driven via regional sales offices) and transaction-based generic API manufacturing/sales from its commercial portfolio. Go-to-market is enterprise field sales executed through six regional sales offices (Italy, Eastern EU, Central EU, Japan, USA, India) under the CBC Global Gateway initiative, supplemented by an event-driven demand-generation motion across CPHI (Japan/Americas/China/India/Milano), CDMO Live, World ADC, BOS Basel, DCAT Week, JSPC, and Expo Osaka 2025. The company is not publicly listed (capital stock €15 million), employs 101–250 people, and has received multi-year recognition including the 2025 CDMO Leadership Awards (Small Molecule API International), EcoVadis Gold Medal (top 5% globally), Premio Felix Nazionale, and the 2023 CPhI CEO of the Year for CEO Enrico Zodio.

Name

Procos

Legal name

PROCOS S.P.A.

Website

https://procos.it

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

101–250 employees

Short description

Procos S.P.A. is an Italian CDMO specializing in custom synthesis, generic API manufacturing, and HPAPI production from a cGMP facility in Cameri, serving innovator and generic pharmaceutical companies globally under Japanese parent CBC Co. Ltd.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Active pharmaceutical ingredients
• Contract development manufacturing
• Custom synthesis services
• Generic API manufacturing
• Highly potent API production

Headquarters

HQ city

Cameri

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Custom Synthesis / CDMO Services: PROCOS develops and manufactures APIs and intermediates on an exclusive basis for pharmaceutical clients, spanning from preclinical through clinical and commercial supply phases. This includes process development, optimization, analytical method development, and regulatory support.
2. Generic API Manufacturing & Sales: PROCOS manufactures and sells generic Active Pharmaceutical Ingredients from its portfolio of over 30 commercial products across diverse therapeutic classes, serving the global generic drug market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Procos S.P.A. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development, scale-up, and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and Highly Potent Active Pharmaceutical Ingredients (HPAPI) for the pharmaceutical industry. Its offering includes custom synthesis services, generic API manufacturing across a portfolio of 40+ commercial products, R&D services for process development and optimization, and specialized HPAPI production under cGMP compliance.

Product overview

PROCOS S.P.A. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development, scale-up, and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and related services for the pharmaceutical industry. The company operates through four interconnected service lines: Custom Synthesis (tailored API development for new drug candidates), Generic API Manufacturing (portfolio of 40+ commercial APIs), R&D Services (process development and optimization), and HPAPI Unit (high-potency API production). Production is supported by specialized facilities including Kilolab, Minilab, Small Scale GMP, and Flow Chemistry Technology platforms, all operating under cGMP compliance with regulatory approvals from FDA, PMDA, and AIFA.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Synthesis Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Chiesi GroupcoreStrategic or Co-development Partner · 1 January 2025PROCOS received the 'Best Partner for People and Planet' award at Chiesi Group's Partnership Day 2025, recognizing collaboration on sustainability and innovation across the pharmaceutical value chain. PROCOS participated in Chiesi's DeCarbon Talk on decarbonization strategies and future goals.
• DuPontminorOthersDuPont is a manufacturer of Tyvek protective garments. PROCOS partners with DuPont for the supply of protective equipment used in HPAPI manufacturing operations where operator safety is critical.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: Global CDMO leader offering small-molecule API manufacturing alongside biologics, cell & gene therapy, and other modalities — a much larger incumbent that competes with Procos on commercial-scale small-molecule and HPAPI programs.
• Teva API: API manufacturing division of Teva Pharmaceutical Industries, one of the world's largest API producers with extensive generic and custom synthesis capabilities — competes broadly across Procos's commercial API portfolio.
• Johnson Matthey (Health): Diversified chemicals company with a Health division providing API custom development and manufacturing services, including controlled substances and HPAPIs — overlaps with Procos's custom synthesis offering.

Direct peers

• Cerbios-Pharma: Swiss-Italian CDMO offering API development and manufacturing including HPAPIs and biologics, with a comparable multi-purpose facility model and focus on high-potency compounds.
• Hovione: Portuguese CDMO focused on small-molecule API development and manufacturing with strong HPAPI and inhalation capability, comparable mid-sized European competitor with similar end-to-end service model.
• Siegfried Holding: Swiss-headquartered CDMO specializing in small-molecule API manufacturing including HPAPI, with comparable end-to-end services from R&D to commercial supply and multi-site European manufacturing footprint.
• EUROAPI: European API CDMO spun out of Sanofi, offering small-molecule API development, custom synthesis, and generic API supply across multiple therapeutic areas — a directly comparable peer in scale and service portfolio.
• Olon S.p.A. Italian API manufacturer and CDMO with similar generic API portfolio and custom synthesis capabilities, including HPAPI production — a direct geographic and product category competitor.
• Fabbrica Italiana Sintetici (FIS): Italian API CDMO with comparable custom synthesis and generic API capabilities, serving global pharma from a multi-site Italian manufacturing base — a direct regional competitor.

Emerging players

• Aesica Pharmaceuticals (Worthington Enterprises / MedPharma): European API CDMO providing custom development and manufacturing services for small-molecule APIs, partially overlapping with Procos on contract manufacturing engagements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/procos
• LinkedInlinkedin.com/company/procos-spa
• Instagraminstagram.com/procos_spa

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Procos